HIV Testing Recommendations
HIV screening should be performed routinely for all adolescents and adults aged 15-65 years using an opt-out approach, where patients are notified that testing will be performed unless they decline, without requiring separate written consent. 1
Core Screening Approach
Universal Screening
- Offer HIV testing to all patients aged 15-65 years in all healthcare settings, regardless of perceived risk 2
- Use opt-out screening: inform patients orally or in writing that HIV testing will be performed unless they decline 1
- General informed consent for medical care is sufficient—do not require separate HIV-specific consent forms 1
- Document patient refusal in the medical record if testing is declined 1
High-Risk Populations Requiring Annual Screening
Persons at high risk should be screened at least annually 1:
- Anyone attending STD clinics or seeking STD treatment
- Men who have sex with men (MSM)
- Persons who inject drugs
- Persons who exchange sex for money or drugs
- Sex partners of HIV-infected persons
- Persons with multiple sexual partners
Screening Intervals
- One-time screening for all adolescents and adults aged 15-65 years 3, 2
- Annual screening for high-risk individuals 1, 3
- For very high-risk populations, annual rescreening is appropriate; for increased-risk individuals, consider rescreening every 3-5 years 3
- Younger adolescents (<15 years) and older adults (>65 years) should be screened based on individual risk factors 3, 2
Special Populations
Pregnant Women
- Screen all pregnant women during the first trimester 2
- Rescreen in the third trimester for women at high risk or in high-prevalence settings 2
- Screen women who present in labor or delivery with unknown HIV status 2
- Rescreen in subsequent pregnancies even if previously negative 3
Diagnostic Testing (Symptomatic Patients)
All patients with signs/symptoms of HIV infection or opportunistic illness must be tested 1:
- For suspected acute HIV infection (flu-like illness with recent high-risk exposure): use plasma HIV RNA test in conjunction with HIV antibody test to detect infection during the window period 1
- General medical consent is sufficient for diagnostic testing 1
Testing Methods
The conventional approach uses:
- Fourth-generation combination tests (p24 antigen + HIV antibodies) as the preferred screening method—these reduce the window period to as few as 14 days 4
- Repeatedly reactive immunoassay followed by confirmatory Western blot or immunofluorescent assay (sensitivity and specificity >99.5%) 3
- Rapid HIV tests (blood or oral fluid) provide results in 5-40 minutes with similar accuracy, but positive results require confirmation 3
Critical Implementation Points
What NOT to Require
- Do not require separate written consent for HIV screening 1
- Do not mandate prevention counseling as part of routine screening programs (though strongly encouraged for high-risk individuals in appropriate settings like STD clinics) 1
- Do not use risk-based screening alone in routine healthcare settings—this misses many infections 1
Essential Follow-Up
Linking HIV-positive patients to care is mandatory—screening without linkage to clinical care and prevention services provides no benefit 1. Ensure access to:
- Antiretroviral therapy
- Clinical monitoring
- Prevention counseling and support services 1
Common Pitfalls to Avoid
- Failing to test due to perceived low risk: approximately 25% of HIV-infected persons are unaware of their status, and many present late in disease 1, 2
- Missing acute HIV infection: maintain high suspicion in patients with compatible symptoms and recent high-risk behavior; standard antibody tests may be negative during acute infection 1
- Creating barriers with excessive consent requirements: simplified consent processes increase testing rates 1
Rationale for Routine Screening
HIV screening is cost-effective even in low-prevalence settings (≥0.1% prevalence), comparable to other established chronic disease screening programs 1. Early diagnosis and treatment: